{"transactions":[{"id":1358370,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Class A Common Stock","published_at":"2024-11-19T23:26:37.000Z","date":"2024-11-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":4187,"price":6.175,"value":25854.725,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units."}],"balance_after":225429,"source":{"system":"sec-edgar","filing":"0001601830-24-000215","document":"wk-form4_1732058791.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000215/wk-form4_1732058791.xml","form_type":"4"}},{"id":1428817,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Class A Common Stock","published_at":"2024-08-19T23:09:42.000Z","date":"2024-08-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":14146,"price":6.69,"value":94636.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units."}],"balance_after":229616,"source":{"system":"sec-edgar","filing":"0001601830-24-000127","document":"wk-form4_1724108977.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000127/wk-form4_1724108977.xml","form_type":"4"}},{"id":1510511,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Class A Common Stock","published_at":"2024-05-17T23:12:02.000Z","date":"2024-05-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":867,"price":10.01,"value":8678.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units."}],"balance_after":243762,"source":{"system":"sec-edgar","filing":"0001601830-24-000058","document":"wk-form4_1715987513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000058/wk-form4_1715987513.xml","form_type":"4"}},{"id":1645344,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (RIght to Buy)","published_at":"2024-02-14T00:03:37.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":99537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter."}],"balance_after":99537,"derivative":{"exercise_price":10.09,"expiration_date":"2034-02-09","underlying":"Class A Common Stock","underlying_shares":99537},"source":{"system":"sec-edgar","filing":"0001209191-24-003241","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919124003241/doc4.xml","form_type":"4"}},{"id":1645343,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Class A Common Stock","published_at":"2024-02-14T00:03:37.000Z","date":"2024-02-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":1892,"price":10.09,"value":19090.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units."}],"balance_after":244629,"source":{"system":"sec-edgar","filing":"0001209191-24-003241","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919124003241/doc4.xml","form_type":"4"}},{"id":1645342,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Class A Common Stock","published_at":"2024-02-14T00:03:37.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":49768,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2024 and every three months thereafter."}],"balance_after":246521,"source":{"system":"sec-edgar","filing":"0001209191-24-003241","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919124003241/doc4.xml","form_type":"4"}},{"id":1645341,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Class A Common Stock","published_at":"2024-02-14T00:03:37.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":6040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This RSU vested immediately upon the grant date."}],"balance_after":196753,"source":{"system":"sec-edgar","filing":"0001209191-24-003241","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919124003241/doc4.xml","form_type":"4"}},{"id":1863487,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-07T23:36:49.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":381426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to one fourth (1/4th) of the shares subject to the option on June 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":381426,"derivative":{"exercise_price":8.77,"expiration_date":"2033-06-01","underlying":"Class A Common Stock","underlying_shares":381426},"source":{"system":"sec-edgar","filing":"0001209191-23-035239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123035239/doc4.xml","form_type":"4"}},{"id":1863486,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Class A Common Stock","published_at":"2023-06-07T23:36:49.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":190713,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This RSU vests as to one fourth (1/4th) of the units subject to the RSU on August 15, 2024 and one sixteenth (1/16th) every three months thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":190713,"source":{"system":"sec-edgar","filing":"0001209191-23-035239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123035239/doc4.xml","form_type":"4"}},{"id":2044676,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-26T16:15:43.000Z","date":"2023-01-24","kind":"grant","acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 24, 2024, with the remainder vesting in 12 equal quarterly installments thereafter."}],"balance_after":190000,"derivative":{"exercise_price":0.74,"expiration_date":"2033-01-23","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0000899243-23-002758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000089924323002758/doc4.xml","form_type":"4"}},{"id":2153876,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-09-20T16:15:44.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 16, 2022, the reporting person was granted 80,000 restricted stock units, vesting on June 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On September 16, 2022, the reporting person was granted 80,000 restricted stock units, vesting on June 30, 2023."}],"balance_after":80000,"derivative":{"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-22-031587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000089924322031587/doc4.xml","form_type":"4"}},{"id":2281738,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-05-04T16:29:09.000Z","date":"2022-05-02","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On May 2, 2022, the reporting person was granted 20,000 restricted stock units, with one-third vesting on May 2, 2023, and the remainder vesting in two equal yearly installments on each of the one-year anniversaries thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On May 2, 2022, the reporting person was granted 20,000 restricted stock units, with one-third vesting on May 2, 2023, and the remainder vesting in two equal yearly installments on each of the one-year anniversaries thereafter."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-016604","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000089924322016604/doc4.xml","form_type":"4"}},{"id":2281737,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-04T16:29:09.000Z","date":"2022-05-02","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on May 2, 2023, with the remainder vesting in 12 equal quarterly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":3.26,"expiration_date":"2032-05-01","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-22-016604","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000089924322016604/doc4.xml","form_type":"4"}},{"id":2546879,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-10-06T18:02:41.000Z","date":"2021-10-05","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":137610,"derivative":{"exercise_price":1.89,"expiration_date":"2029-07-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-059850","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121059850/doc4.xml","form_type":"4"}},{"id":2546878,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-06T18:02:41.000Z","date":"2021-10-05","kind":"sale","acquired":false,"shares":1289,"price":32.0637,"value":41330.1093,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.87 to $32.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-059850","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121059850/doc4.xml","form_type":"4"}},{"id":2546877,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-06T18:02:41.000Z","date":"2021-10-05","kind":"sale","acquired":false,"shares":7803,"price":31.303,"value":244257.309,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.87 to $31.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":1289,"source":{"system":"sec-edgar","filing":"0001209191-21-059850","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121059850/doc4.xml","form_type":"4"}},{"id":2546876,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-06T18:02:41.000Z","date":"2021-10-05","kind":"sale","acquired":false,"shares":5908,"price":30.2577,"value":178762.4916,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":9092,"source":{"system":"sec-edgar","filing":"0001209191-21-059850","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121059850/doc4.xml","form_type":"4"}},{"id":2546875,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-06T18:02:41.000Z","date":"2021-10-05","kind":"exercise","acquired":true,"shares":15000,"price":1.89,"value":28350.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-059850","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121059850/doc4.xml","form_type":"4"}},{"id":2574351,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-09-09T16:53:43.000Z","date":"2021-09-07","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":167610,"derivative":{"exercise_price":1.89,"expiration_date":"2029-07-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-055307","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121055307/doc4.xml","form_type":"4"}},{"id":2574350,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-09T16:53:43.000Z","date":"2021-09-07","kind":"sale","acquired":false,"shares":4640,"price":37.7876,"value":175334.464,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $38.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-055307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121055307/doc4.xml","form_type":"4"}},{"id":2574349,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-09T16:53:43.000Z","date":"2021-09-07","kind":"sale","acquired":false,"shares":2873,"price":36.9234,"value":106080.9282,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.50 to $37.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":4640,"source":{"system":"sec-edgar","filing":"0001209191-21-055307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121055307/doc4.xml","form_type":"4"}},{"id":2574348,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-09T16:53:43.000Z","date":"2021-09-07","kind":"sale","acquired":false,"shares":7487,"price":35.9112,"value":268867.1544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $36.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":7513,"source":{"system":"sec-edgar","filing":"0001209191-21-055307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121055307/doc4.xml","form_type":"4"}},{"id":2574347,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-09T16:53:43.000Z","date":"2021-09-07","kind":"exercise","acquired":true,"shares":15000,"price":1.89,"value":28350.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-055307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121055307/doc4.xml","form_type":"4"}},{"id":2609733,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-08-09T16:26:33.000Z","date":"2021-08-05","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":167610,"derivative":{"exercise_price":1.89,"expiration_date":"2029-07-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-050404","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121050404/doc4.xml","form_type":"4"}},{"id":2609732,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-09T16:26:33.000Z","date":"2021-08-05","kind":"sale","acquired":false,"shares":100,"price":32.63,"value":3263.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-050404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121050404/doc4.xml","form_type":"4"}},{"id":2609731,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-09T16:26:33.000Z","date":"2021-08-05","kind":"sale","acquired":false,"shares":6721,"price":32.1457,"value":216051.2497,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0001209191-21-050404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121050404/doc4.xml","form_type":"4"}},{"id":2609730,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-09T16:26:33.000Z","date":"2021-08-05","kind":"sale","acquired":false,"shares":2063,"price":31.0278,"value":64010.3514,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.60 to $31.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":6821,"source":{"system":"sec-edgar","filing":"0001209191-21-050404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121050404/doc4.xml","form_type":"4"}},{"id":2609729,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-09T16:26:33.000Z","date":"2021-08-05","kind":"sale","acquired":false,"shares":6116,"price":29.9329,"value":183069.6164,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.35 to $30.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":8884,"source":{"system":"sec-edgar","filing":"0001209191-21-050404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121050404/doc4.xml","form_type":"4"}},{"id":2609728,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-09T16:26:33.000Z","date":"2021-08-05","kind":"exercise","acquired":true,"shares":15000,"price":1.89,"value":28350.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-050404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121050404/doc4.xml","form_type":"4"}},{"id":2626924,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-07-22T18:13:00.000Z","date":"2021-07-20","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":95000,"derivative":{"exercise_price":31.23,"expiration_date":"2031-07-19","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-21-047841","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121047841/doc4.xml","form_type":"4"}},{"id":2637766,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-07-08T17:41:32.000Z","date":"2021-07-06","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":182610,"derivative":{"exercise_price":1.89,"expiration_date":"2029-07-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-046013","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121046013/doc4.xml","form_type":"4"}},{"id":2637765,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-07-08T17:41:32.000Z","date":"2021-07-06","kind":"sale","acquired":false,"shares":300,"price":28.8433,"value":8652.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $28.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-046013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121046013/doc4.xml","form_type":"4"}},{"id":2637764,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-07-08T17:41:32.000Z","date":"2021-07-06","kind":"sale","acquired":false,"shares":4255,"price":28.1343,"value":119711.4465,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.75 to $28.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":300,"source":{"system":"sec-edgar","filing":"0001209191-21-046013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121046013/doc4.xml","form_type":"4"}},{"id":2637763,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-07-08T17:41:32.000Z","date":"2021-07-06","kind":"sale","acquired":false,"shares":10445,"price":27.1654,"value":283742.603,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.74 to $27.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":4555,"source":{"system":"sec-edgar","filing":"0001209191-21-046013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121046013/doc4.xml","form_type":"4"}},{"id":2637762,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-07-08T17:41:32.000Z","date":"2021-07-06","kind":"exercise","acquired":true,"shares":15000,"price":1.89,"value":28350.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-046013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121046013/doc4.xml","form_type":"4"}},{"id":2675020,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-09T18:24:28.000Z","date":"2021-06-07","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":197610,"derivative":{"exercise_price":1.89,"expiration_date":"2029-06-16","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-039261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121039261/doc4.xml","form_type":"4"}},{"id":2675019,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-09T18:24:28.000Z","date":"2021-06-07","kind":"sale","acquired":false,"shares":12700,"price":32.7295,"value":415664.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.21 to $33.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-039261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121039261/doc4.xml","form_type":"4"}},{"id":2675018,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-09T18:24:28.000Z","date":"2021-06-07","kind":"sale","acquired":false,"shares":900,"price":31.6244,"value":28461.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $32.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":12700,"source":{"system":"sec-edgar","filing":"0001209191-21-039261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121039261/doc4.xml","form_type":"4"}},{"id":2675017,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-09T18:24:28.000Z","date":"2021-06-07","kind":"sale","acquired":false,"shares":1400,"price":30.3541,"value":42495.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.97 to $30.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":13600,"source":{"system":"sec-edgar","filing":"0001209191-21-039261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121039261/doc4.xml","form_type":"4"}},{"id":2675016,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-09T18:24:28.000Z","date":"2021-06-07","kind":"exercise","acquired":true,"shares":15000,"price":1.89,"value":28350.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-039261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121039261/doc4.xml","form_type":"4"}},{"id":2720478,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-05-10T16:37:57.000Z","date":"2021-05-05","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":212610,"derivative":{"exercise_price":1.89,"expiration_date":"2029-06-16","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-031248","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121031248/doc4.xml","form_type":"4"}},{"id":2720477,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-05-10T16:37:57.000Z","date":"2021-05-05","kind":"sale","acquired":false,"shares":1109,"price":41.0682,"value":45544.6338,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.70 to $41.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-031248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121031248/doc4.xml","form_type":"4"}},{"id":2720476,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-05-10T16:37:57.000Z","date":"2021-05-05","kind":"sale","acquired":false,"shares":10476,"price":40.2967,"value":422148.2292,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.70 to $40.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":1109,"source":{"system":"sec-edgar","filing":"0001209191-21-031248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121031248/doc4.xml","form_type":"4"}},{"id":2720475,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-05-10T16:37:57.000Z","date":"2021-05-05","kind":"sale","acquired":false,"shares":3415,"price":39.3555,"value":134399.0325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.70 to $39.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":11585,"source":{"system":"sec-edgar","filing":"0001209191-21-031248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121031248/doc4.xml","form_type":"4"}},{"id":2720474,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-05-10T16:37:57.000Z","date":"2021-05-05","kind":"exercise","acquired":true,"shares":15000,"price":1.89,"value":28350.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-031248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121031248/doc4.xml","form_type":"4"}},{"id":2735493,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-29T17:14:44.000Z","date":"2021-04-27","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":227610,"derivative":{"exercise_price":1.89,"expiration_date":"2029-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-029033","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121029033/doc4.xml","form_type":"4"}},{"id":2735492,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-29T17:14:44.000Z","date":"2021-04-27","kind":"sale","acquired":false,"shares":1711,"price":36.1137,"value":61790.5407,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.08 to $36.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-029033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121029033/doc4.xml","form_type":"4"}},{"id":2735491,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-29T17:14:44.000Z","date":"2021-04-27","kind":"sale","acquired":false,"shares":15601,"price":35.6759,"value":556579.7159,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.08 to $36.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":1711,"source":{"system":"sec-edgar","filing":"0001209191-21-029033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121029033/doc4.xml","form_type":"4"}},{"id":2735490,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-29T17:14:44.000Z","date":"2021-04-27","kind":"sale","acquired":false,"shares":7688,"price":34.6615,"value":266477.612,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.05 to $35.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":17312,"source":{"system":"sec-edgar","filing":"0001209191-21-029033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121029033/doc4.xml","form_type":"4"}},{"id":2735489,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-29T17:14:44.000Z","date":"2021-04-27","kind":"exercise","acquired":true,"shares":25000,"price":1.89,"value":47250.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-21-029033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121029033/doc4.xml","form_type":"4"}},{"id":2742721,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-21T19:56:10.000Z","date":"2021-04-19","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":252610,"derivative":{"exercise_price":1.89,"expiration_date":"2029-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-027874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121027874/doc4.xml","form_type":"4"}},{"id":2742720,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-21T19:56:10.000Z","date":"2021-04-19","kind":"sale","acquired":false,"shares":4000,"price":31.2692,"value":125076.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.19 to $31.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-027874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121027874/doc4.xml","form_type":"4"}},{"id":2742719,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-21T19:56:10.000Z","date":"2021-04-19","kind":"sale","acquired":false,"shares":21000,"price":30.8225,"value":647272.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.19 to $31.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001209191-21-027874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121027874/doc4.xml","form_type":"4"}},{"id":2742718,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-21T19:56:10.000Z","date":"2021-04-19","kind":"exercise","acquired":true,"shares":25000,"price":1.89,"value":47250.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-21-027874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121027874/doc4.xml","form_type":"4"}},{"id":2748268,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-15T19:09:37.000Z","date":"2021-04-08","kind":"exercise","acquired":false,"shares":9617,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vested as to 25% of the total shares monthly beginning on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":277610,"derivative":{"exercise_price":1.89,"expiration_date":"2029-06-16","underlying":"Common Stock","underlying_shares":9617},"source":{"system":"sec-edgar","filing":"0001209191-21-026872","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121026872/doc4.xml","form_type":"4"}},{"id":2748267,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-15T19:09:37.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":3549,"price":39.5584,"value":140392.7616,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.38 to $40.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-026872","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121026872/doc4.xml","form_type":"4"}},{"id":2748266,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-15T19:09:37.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":1293,"price":38.9972,"value":50423.3796,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.38 to $39.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":3549,"source":{"system":"sec-edgar","filing":"0001209191-21-026872","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121026872/doc4.xml","form_type":"4"}},{"id":2748265,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-15T19:09:37.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":1501,"price":37.8283,"value":56780.2783,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.38 to $38.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":4842,"source":{"system":"sec-edgar","filing":"0001209191-21-026872","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121026872/doc4.xml","form_type":"4"}},{"id":2748264,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-15T19:09:37.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":3274,"price":37.036,"value":121255.864,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.37 to $37.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":6343,"source":{"system":"sec-edgar","filing":"0001209191-21-026872","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121026872/doc4.xml","form_type":"4"}},{"id":2748263,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-15T19:09:37.000Z","date":"2021-04-08","kind":"exercise","acquired":true,"shares":9617,"price":1.89,"value":18176.13,"ownership":{"direct":true},"balance_after":9617,"source":{"system":"sec-edgar","filing":"0001209191-21-026872","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121026872/doc4.xml","form_type":"4"}},{"id":2751829,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-09T17:50:45.000Z","date":"2021-04-07","kind":"exercise","acquired":false,"shares":15383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vested as to 25% of the total shares monthly beginning on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":287227,"derivative":{"exercise_price":1.89,"expiration_date":"2029-06-16","underlying":"Common Stock","underlying_shares":15383},"source":{"system":"sec-edgar","filing":"0001209191-21-026291","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121026291/doc4.xml","form_type":"4"}},{"id":2751828,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-09T17:50:45.000Z","date":"2021-04-07","kind":"sale","acquired":false,"shares":7083,"price":39.6888,"value":281115.7704,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.30 to $40.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-026291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121026291/doc4.xml","form_type":"4"}},{"id":2751827,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-09T17:50:45.000Z","date":"2021-04-07","kind":"sale","acquired":false,"shares":8300,"price":39.025,"value":323907.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.30 to $39.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":7083,"source":{"system":"sec-edgar","filing":"0001209191-21-026291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121026291/doc4.xml","form_type":"4"}},{"id":2751826,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":85901,"kind":"person","name":"Mauro David J","position":1,"cik":"0001621172","reported_name":"Mauro David J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-09T17:50:45.000Z","date":"2021-04-07","kind":"exercise","acquired":true,"shares":15383,"price":1.89,"value":29073.87,"ownership":{"direct":true},"balance_after":15383,"source":{"system":"sec-edgar","filing":"0001209191-21-026291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1621172/000120919121026291/doc4.xml","form_type":"4"}}]}